Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for ...

VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.

The proposed spin-off will establish Cortigent as an independent, publicly traded company, enabling it to pursue specialized research and clinical trials while unlocking greater strategic and ...

Vivani Medical (Nasdaq:VANI) announced that it filed a Form 10 registration statement with the SEC to spin off its ...

Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its ...

Vivani Medical plans to spin off Cortigent, allowing both companies to focus on their specialized therapeutic areas by Q3 2025. Vivani Medical, Inc. has announced plans to spin off its subsidiary ...

Vivani’s CEO, Adam Mendelsohn, Ph.D., noted the importance of this milestone in establishing Cortigent as an independent entity dedicated to pioneering neurostimulation technology. Cortigent’s ...

ALAMEDA, Calif. - Vivani Medical, Inc. (NASDAQ: VANI), a biopharmaceutical company specializing in long-acting drug implants, announced the filing of a Form 10 registration with the SEC for its ...

ALAMEDA, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani” or the "Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting ...

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion ...

Cortigent is developing the Orion ® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve ...